- Home
- PLX vs LARK Comparison
PLX vs LARK Comparison
Compare PLX & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- LARK
- Stock Information
- Founded
- PLX 1993
- LARK 1885
- Country
- PLX United States
- LARK United States
- Employees
- PLX N/A
- LARK N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- LARK Major Banks
- Sector
- PLX Health Care
- LARK Finance
- Exchange
- PLX Nasdaq
- LARK Nasdaq
- Market Cap
- PLX 160.2M
- LARK 167.5M
- IPO Year
- PLX 1998
- LARK N/A
- Fundamental
- Price
- PLX $1.55
- LARK $29.10
- Analyst Decision
- PLX Strong Buy
- LARK
- Analyst Count
- PLX 1
- LARK 0
- Target Price
- PLX $15.00
- LARK N/A
- AVG Volume (30 Days)
- PLX 1.4M
- LARK 19.8K
- Earning Date
- PLX 05-09-2025
- LARK 04-30-2025
- Dividend Yield
- PLX N/A
- LARK 2.89%
- EPS Growth
- PLX N/A
- LARK 27.69
- EPS
- PLX 0.05
- LARK 2.59
- Revenue
- PLX $59,764,000.00
- LARK $60,798,000.00
- Revenue This Year
- PLX $65.02
- LARK N/A
- Revenue Next Year
- PLX $57.34
- LARK N/A
- P/E Ratio
- PLX $32.18
- LARK $11.24
- Revenue Growth
- PLX 0.18
- LARK 9.30
- 52 Week Low
- PLX $0.82
- LARK $17.53
- 52 Week High
- PLX $3.10
- LARK $31.04
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- LARK 50.94
- Support Level
- PLX $1.54
- LARK $28.74
- Resistance Level
- PLX $1.79
- LARK $30.10
- Average True Range (ATR)
- PLX 0.11
- LARK 0.81
- MACD
- PLX -0.02
- LARK -0.09
- Stochastic Oscillator
- PLX 27.27
- LARK 43.18
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.